The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.

Détails

Ressource 1Télécharger: BIB_D98D7D431DD0.P001.pdf (384.18 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_D98D7D431DD0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Périodique
European Journal of Nuclear Medicine and Molecular Imaging
Auteur(s)
Goerres G.W., Stupp R., Barghouth G., Hany T.F., Pestalozzi B., Dizendorf E., Schnyder P., Luthi F., von Schulthess G.K., Leyvraz S.
ISSN
1619-7070
Statut éditorial
Publié
Date de publication
02/2005
Peer-reviewed
Oui
Volume
32
Numéro
2
Pages
153-162
Langue
anglais
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; Journal Article
Résumé
PURPOSE: Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the gastrointestinal tract that are unresponsive to standard sarcoma chemotherapy. Imaging of GIST patients is done with structural and functional methods such as contrast-enhanced helical computed tomography (ceCT) and positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG). The aim of this study was to compare the prognostic power of PET and ceCT and to evaluate the clinical role of PET/CT imaging. METHODS: All patients with GIST undergoing PET or PET/CT examinations were prospectively included in this study, and the median overall survival, time to progression and treatment duration were documented. The prognostic significance of PET and ceCT criteria of treatment response was assessed and PET/CT was compared with PET and ceCT imaging. Data for 34 patients (19 male, 15 female, 21-76 years) undergoing PET or PET/CT for staging or restaging were analysed. RESULTS: In 28 patients, PET/CT and ceCT were available after introduction of treatment with the tyrosine kinase inhibitor imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). Patients without FDG uptake after the start of treatment had a better prognosis than patients with residual activity. In contrast, ceCT criteria provided insufficient prognostic power. However, more lesions were found on ceCT images than on PET images, and FDG uptake was sometimes very variable. PET/CT delineated active lesions better than did the combination of PET and ceCT imaging. CONCLUSION: Both PET and PET/CT provide important prognostic information and have an impact on clinical decision-making in GIST patients. PET/CT precisely delineates lesions and thus allows for the correct planning of surgical interventions.
Mots-clé
Adult, Aged, Antineoplastic Agents/therapeutic use, Disease-Free Survival, Female, Fluorodeoxyglucose F18/diagnostic use, Follow-Up Studies, Gastrointestinal Neoplasms/diagnosis, Gastrointestinal Neoplasms/drug therapy, Humans, Longitudinal Studies, Male, Middle Aged, Piperazines/therapeutic use, Positron-Emission Tomography/methods, Prognosis, Pyrimidines/therapeutic use, Radiopharmaceuticals/diagnostic use, Reproducibility of Results, Sensitivity and Specificity, Survival Analysis, Switzerland/epidemiology, Tomography, X-Ray Computed/methods, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/04/2008 13:19
Dernière modification de la notice
20/08/2019 16:58
Données d'usage